...nce. Despite the recognized need for new antimicrobials for clinical use, the reality is that only two new classes of antibiotics have been brought to market in the last 30 years and many drug developers have left the field. This urgency is especially true when considering resistant Gram-negative infections where carbapenem-resistance is rising and use of drugs of last resort, such as colistin, ...